Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 14 April 2026Expected publication date: 6 May 2027
Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 16 April 2026Expected publication date: TBC
Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma ID6549Status:Topic prioritisation | In consultationProgramme:Technology appraisal guidanceConsultation end date: 16 April 2026Expected publication date: TBC
Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 14 April 2026Expected publication date: TBC